Mayer Brown represents HDL Therapeutics in merger with Swiftmerge Acquisition Corp.

A Mayer Brown team represented HDL Therapeutics, Inc., a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia, in its definitive merger agreement with Swiftmerge Acquisition Corp., a special purpose acquisition company, in a transaction valued at $480 million. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions.

The team included Corporate & Securities partners Kevin Sheridan (New York) and Andrew Noreuil (Chicago) and counsel Ranjit Hakim (Chicago) and Employment & Benefits partner Ryan Liebl (Chicago).

###